Cargando…

Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?

BACKGROUND: The time interval between palliative thoracic radiotherapy and bevacizumab treatment strongly influences the frequency of adverse events (AEs) when both are concurrently applied to patients with advanced lung cancer. Herein, we aimed to elucidate the optimal time interval between the tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiu, Weigang, Guo, Xiaotong, Yu, Min, Li, Yanying, Xu, Yong, Zhu, Jiang, Luo, Jingjing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234832/ https://www.ncbi.nlm.nih.gov/pubmed/35770233 http://dx.doi.org/10.1177/11795549221106462

Ejemplares similares

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
por: Hofman, Véronique, et al.
Publicado: (2022)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC
por: Kim, Edward S., et al.
Publicado: (2021)

A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC
por: Piha-Paul, Sarina, et al.
Publicado: (2022)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
por: Fujimoto, Daichi, et al.
Publicado: (2021)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016)

Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021
por: Hess, Lisa M., et al.
Publicado: (2022)

Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study
por: Estevinho, Fernanda, et al.
Publicado: (2012)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Shan, Feiyu, et al.
Publicado: (2018)

Campylobacteremia in stage IV gliosarcoma with bevacizumab treatment
por: Liu, Ping
Publicado: (2012)

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
por: Casadevall, David, et al.
Publicado: (2015)

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019)

The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis
por: Li, Duo, et al.
Publicado: (2023)

Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices
por: Liu, Stephen V., et al.
Publicado: (2022)

Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study
por: Wallrabenstein, Till, et al.
Publicado: (2023)

A comparative study of different dose fractionations schedule of thoracic radiotherapy for pain palliation and health-related quality of life in metastatic NSCLC
por: Sau, Sourav, et al.
Publicado: (2014)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Radiotherapy improves the survival of patients with stage IV NSCLC: A propensity score matched analysis of the SEER database
por: Zhang, Rui, et al.
Publicado: (2018)

Different fractionation regimes in palliative thoracic radiotherapy: Some facets
por: Sharma, Mukesh, et al.
Publicado: (2015)

The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Zhou, Yue, et al.
Publicado: (2021)

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
por: Tsutani, Yasuhiro, et al.
Publicado: (2018)

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study
por: Kawachi, Hayato, et al.
Publicado: (2022)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
por: Hayashi, Hidetoshi, et al.
Publicado: (2011)

From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report
por: Vernmark, Karolina, et al.
Publicado: (2015)

Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer
por: Song, Xinyu, et al.
Publicado: (2018)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Zhang, Jie, et al.
Publicado: (2021)

Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study
por: Jiang, Qian, et al.
Publicado: (2019)

Developing Preoperative Nomograms to Predict Any-Stage and Stage III-IV Endometriosis in Infertile Women
por: Guo, Zaixin, et al.
Publicado: (2020)

Radical thoracic radiotherapy may provide favorable outcomes for stage IV non‐small cell lung cancer
por: Wang, Jingbo, et al.
Publicado: (2015)

Bevacizumab in the treatment of NSCLC: patient selection and perspectives
por: Russo, Alessia E, et al.
Publicado: (2017)

An Open‐Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non‐Small Cell Lung Cancer
por: Patil, Pradnya Dinkar, et al.
Publicado: (2019)

Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR‐mutant and EGFR‐wild type nonsquamous non‐small cell lung cancer
por: Huang, Yu‐Chen, et al.
Publicado: (2018)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Palliative care at any stage of amyotrophic lateral sclerosis: a prospective feasibility study
por: Zwicker, Jocelyn, et al.
Publicado: (2023)

Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
por: Ren, Shengxiang, et al.
Publicado: (2022)

Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
por: Gadgeel, Shirish, et al.
Publicado: (2022)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
por: Sugisaka, Jun, et al.
Publicado: (2023)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
por: Ninomiya, Kiichiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6g6mqqvbr4omhluofil1bcpq9n